Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products.

Analytical chemistry Polymeric drug delivery system(s) Protein delivery Regulatory science

Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
09 2023
Historique:
received: 20 01 2023
revised: 03 05 2023
accepted: 03 05 2023
medline: 21 8 2023
pubmed: 10 5 2023
entrez: 9 5 2023
Statut: ppublish

Résumé

Evaluating the in-use stability of a biological product including its compatibility with administration components allows to define handling instructions and potential hold times that retain product quality during dose preparation and administration. The intended drug product usage may involve the dilution of drug formulation into admixtures for infusion and exposure to new interfaces of administration components like intravenous (iv) bags, syringes, and tubing. In-use studies assess the potential impact on product quality by simulating drug handling throughout the defined in-use period. Considering the wide range of in-use conditions and administration components available globally, only limited guidance is available from regulators on expected in-use stability data. A working group reviewed and consolidated industry approaches to assess physicochemical stability of traditional protein-based biological products during clinical development and for commercial use. The insights compiled in this review article can be leveraged across the industry and encompass topics such as representative drug product material and administration components, testing conditions, quality attributes evaluated and respective acceptance criteria, applied quality standards, and regulatory requirements. These practices may help companies in the study design, and they may inform discussions with global regulators.

Identifiants

pubmed: 37160227
pii: S0022-3549(23)00190-9
doi: 10.1016/j.xphs.2023.05.002
pii:
doi:

Substances chimiques

Biological Products 0
Pharmaceutical Preparations 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2332-2346

Informations de copyright

Copyright © 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Markus Blümel (M)

Novartis Pharma AG, Biologics Analytical Development, Lichtstrasse 35, CH-4056 Basel, Switzerland. Electronic address: markus.bluemel@novartis.com.

Jing Liu (J)

Seagen Inc., Pharmaceutical Sciences, 21717 30th Drive S.E., Building 3. Bothell, WA, 98021, USA. Electronic address: liujing97@gmail.com.

Isabella de Jong (I)

Genentech (A Member of the Roche Group), Pharmaceutical Development, 1 DNA Way, South San Francisco, CA, 94080, USA.

Sarah Weiser (S)

Pfizer; Biotherapeutics Pharmaceutical Sciences, 1 Burtt Road, Andover, MA 01810, USA.

Jonas Fast (J)

F. Hoffmann-La Roche Ltd., Pharmaceutical Development & Supplies, PTD Biologics Europe, Grenzacherstrasse 124, CH, 4070 Basel, Switzerland.

Jennifer Litowski (J)

Amgen Inc., Process Development, 360 Binney St., Cambridge, MA, 02141, USA.

Melissa Shuman (M)

GSK, Strategic External Development, Sterile Drug Product Operations, 1250 S. Collegeville Road Collegeville, PA, 19426, USA.

Shyam B Mehta (SB)

Teva Branded Pharmaceutical Products, Drug Product Development and Operations, 145 Brandywine Pkwy, West Chester, PA 19380, USA.

Leanne Amery (L)

AstraZeneca, Dosage Form Design and Development, Aaron Klug Building, Granta Park, Cambridge, Cambridgeshire, CB21 6GH, UK.

David Cheng Thiam Tan (DCT)

AbbVie Inc., North Chicago, IL, USA.

Feng Jia (F)

Biogen, Biologics Drug Product, 225 Binney Street, Cambridge, MA, 02142, USA.

Dushyant Shekhawat (D)

Eli Lilly and Company, Bioproduct Research and Development, Indianapolis, IN, 46285, USA.

Camille Dagallier (C)

Sanofi, Biologics Drug Product Development, 1 impasse des ateliers, 94403 Vitry-Sur-Seine, France.

Mina Emamzadeh (M)

AstraZeneca, Dosage Form Design and Development, Aaron Klug Building, Granta Park, Cambridge, Cambridgeshire, CB21 6GH, UK.

Annette Medina (A)

AstraZeneca, Dosage Form Design and Development, One Medimmune Way, Gaithersburg, MD, 20878, USA.

Camilla Santos (C)

Amgen Inc., Product Quality, 40 Technology Way, West Greenwich, RI, 02817, USA.

Florian Gasser (F)

Novartis Pharma AG, Biologics Analytical Development, Biochemiestrasse 10, 6336 Langkampfen, Austria.

Christian Urban (C)

Sanofi, Biologics Drug Product Development, Industriepark Höchst, D-65926 Frankfurt am Main, Germany.

Articles similaires

Humans Pharmaceutical Preparations Drug Utilization Prescription Drugs

Using Bayh-Dole Act March-In Rights to Lower US Drug Prices.

Lisa Larrimore Ouellette, Bhaven N Sampat
1.00
United States Cross-Sectional Studies Patents as Topic Humans Drugs, Generic
Animals Rumen Methane Fermentation Cannabis
Flurbiprofen Tablets Administration, Oral Drug Compounding Solubility

Classifications MeSH